Tilray's Beverage Bet Grows as Cannabis and Rescheduling Stumble
BrewDog founder bids to buy back UK business James Watt, BrewDog's founder, has formally offered to buy back the UK business from Tilray through his new venture, with 43,000 investors backing him. If successful, Tilray would lose a key asset, shrinking its beverage alcohol base and potentially its future earnings power.
A credible bid for a major Tilray asset could reduce the company's value and is a real negative force.
Record revenue and sharply lower net loss Tilray reported record fiscal 2026 net revenue of $915.5 million, up 11%, while its annual net loss narrowed to $105.2 million from nearly $2.2 billion. That huge improvement in profitability, plus net debt cut to just $700,000, strengthens the balance sheet and supports the stock.
This is the core fundamental improvement that makes Tilray more financially stable and attractive to investors.
Court lets marijuana rescheduling proceed A federal appeals court rejected a request to temporarily block the Trump administration's move to reclassify marijuana to Schedule III. That keeps the process alive, and Tilray sees it as a chance to eventually expand its medical cannabis business into the U.S., a big potential new market.
Rescheduling progress is a major regulatory catalyst that could open the U.S. market to Tilray.
Beverage alcohol surges but cannabis slumps; DEA pauses hearing In its fiscal first quarter, Tilray's beverage alcohol revenue jumped 82.6% while cannabis revenue fell 11.8%. The DEA also paused a cannabis rescheduling hearing, a regulatory setback. The company reaffirmed its fiscal 2027 outlook, but the mixed results and wider-than-expected loss sent shares down 3.4%.
This shows the tug-of-war: strong beverage growth versus weak cannabis and a rescheduling delay, which together drive the stock's recent weakness.